|
|
 |
|
Viewing report
|
|
|
|
2004 HDL CHOLESTEROL - 5th Annual Metabolic Pathways and Drug Targets
Knowledge Press, March 2004, Pages: 412
This publication provides the Conference Documentation for this 5th Annual Metabolic Pathways and Drug Targets Conference.
High cholesterol levels remain a leading cause for atherosclerosis and other cardiovascular diseases, despite the multitude of available therapeutics.
In order to develop new pharmaceutical approaches for elevating HDL it is essential to gain a greater understanding of the various pathways in HDL -C metabolism and their regulation.
In it’s 5th year, this conference provides cutting-edge data on cholesterol efflux, transfer proteins, scavenger receptors, nuclear receptors, hepatic lipase, ABCA1 and apolipoprotein A.
Top experts from industry and academia present powerful strategies for reducing the risk of cardiovascular diseases by improving the atherosclerotic protection.
Discover the latest developments in such topics as:
- The role of ceramide in the modulation of ABCA1-mediated cholesterol efflux
- Understanding the regulation of HDL-C by using natural genetic variation as a tool
- Analysis of SR-BI
- RXR agonists as regulators for dietary cholesterol
- Paraoxonase1 and it’s anti-atherosclerotic properties
- LXR in lipid metabolism
- HDL-raising drugs
- Hepatic Lipase modulates lipoprotein metabolism
- Molecular dynamics of ApoA-I
- ABCA1 / apolipoprotein interactions
Please Note: Documentation are copies of the conference speaker's presentation materials
Customers who bought this item also bought
Dyslipidemia: Opportunities in Cardiovascular Risk Reduction
Preventing Cardiovascular Events: Will HDL Therapeutics Change the Treatment Paradigm?
Competitor Analysis: HDL Raising Therapies
Alzheimer Disease - New Drugs, Markets and Companies
Cardiovascular Drug Delivery - Technologies, Markets and Companies
Nutritional and Metabolic Bases of Cardiovascular Disease
Drug Delivery in Central Nervous System Diseases - Technologies, Markets and Companies
Drug Delivery in Cancer - Technologies, Markets and Companies
Competitor Analysis: Cholesterol Management
Atherosclerosis or Coronary Artery Disease (CAD) Therapeutics - Pipeline Assessment and Market Forecasts to 2018
|
|
|
|
